Shares of Hims & Hers Health plunged Friday after the Food & Drug Administration said a shortage of the active ingredient in ...

Shares of Hims & Hers Health ( HIMS -25.79%) are falling on Friday. The company's stock lost 23.2% as of 1 p.m. ET and lost ...

The ruling shows Novo Nordisk’s confidence that the supply of semaglutide will be stable for now.

The telehealth company has been selling a copycat version of a popular obesity drug during the recent shortage.

UnitedHealth declines following a report that the Justice Department has been investigating the company’s Medicare billing ...

Is Hims & Hers a millionaire-maker in the making? Yes! Or, at least, it can be. There is a possible future where Hims & Hers ...

Hims & Hers Health (HIMS) stock falls as the FDA declares that Novo Nordisk's (NVO) weight loss therapies are no longer in ...

Shares tumbled 21% to $52.22. Over the last year, the stock has surged more than 450%.

Semaglutide is a glucagon-like peptide-1 (GLP-1) that helps regulate blood sugar levels. Because of outsized demand for ...

Shares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 24% in the afternoon session after U.S. Food and Drug Administration (FDA) reported that the shortage of weight-loss drugs such as ...

Hims & Hers Health (NYSE:HIMS) is set to report its earnings on Monday, Feb 24 after market close. HIMS stock plunged over 25 ...

The U.S. FDA declared that Novo Nordisk's weight loss and diabetes drugs, Ozempic and Wegovy, are no longer in shortage.